Eli Lilly (LLY) FCF Margin (2009 - 2026)

Eli Lilly has reported FCF Margin for 18 years, with the latest figure at 15.19% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 1396.0% year-over-year to 15.19%; the trailing twelve-month figure through Mar 2026 stood at 16.36% (up 874.0% YoY), and the FY2025 full-year result was 13.77%, up 542.0% from the prior year.
• FCF Margin for Q1 2026 stood at 15.19%, up from 3.51% in the prior quarter.
• The five-year high for FCF Margin was 38.34% in Q3 2025, with the low at 14.79% in Q4 2023.
• Historically, FCF Margin has averaged 11.2% across 5 years, with a median of 12.52% in 2022.
• Annual changes were most pronounced in 2023 — FCF Margin plunged 3070 bps — and 2024, when it jumped 2201 bps.
• Eli Lilly's FCF Margin stood at 15.91% in 2022, then plunged by 193 bps to 14.79% in 2023, then surged by 149 bps to 7.22% in 2024, then tumbled by 51 bps to 3.51% in 2025, then jumped by 332 bps to 15.19% in 2026.
• The last three FCF Margin figures came in at 15.19% (Q1 2026), 3.51% (Q4 2025), and 38.34% (Q3 2025), per Business Quant data.